Koseki M, Shimamura Y, Maki T, Tamura Y, & Naoi Y (1980) Residues of TPN (tetrachloroisophthalonitrile), captan, diazinon and chinomethionate in vegetables and fruits
Probiotics help restore the gut barrier function that antibiotics compromise
Canadian Access and Considerations Canadian researchers and individuals interested in these compounds face a specific regulatory landscape that differs from other jurisdictions
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days